Cel­gene buys Acety­lon, keeps what it wants and spins the rest back out as Re­ge­na­cy

Months af­ter Cel­gene qui­et­ly passed on a three-year-old op­tion to buy Acety­lon, Cel­gene has come back and snatched what want­ed in a buy­out — al­low­ing the rest to be spun out in­to a new com­pa­ny called Re­ge­na­cy Phar­ma­ceu­ti­cals.

The Big Biotech an­nounced Fri­day af­ter­noon that it had com­plet­ed a deal to buy Boston-based Acety­lon for an un­spec­i­fied sum (Cel­gene paid $100 mil­lion to ac­quire the op­tion) with an eye on world­wide rights to Acety­lon’s se­lec­tive HDAC6 in­hibitor pro­grams and in­tel­lec­tu­al prop­er­ty in on­col­o­gy, neu­rode­gen­er­a­tion, and au­toim­mune dis­ease, in­clud­ing its lead drug can­di­dates citari­no­s­tat (ACY-241) and ri­col­i­no­s­tat (ACY-1215).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER